Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

1.130 +0.050 (+4.63%)
Streaming Delayed Price Updated: 9:58 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapt Therapeutics Inc

< Previous 1 2 3 4 5 Next >
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
Why RAPT Therapeutics Stock Is Surging Today
RAPT Therapeutics Inc (NASDAQ:RAPT) shares are tradin... 
Via Benzinga
How Good Are RAPT Therapeutics's Earnings? | Return On Capital Employed
According to Benzinga Pro data, during Q2, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $869.00 thousand. Earnings were up 2.9%, but RAPT Therapeutics still reported an overall... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021
Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Wedbush boosted Microsoft Corporation (NASDAQ: MSFT) price target from $310 to $325. Microsoft shares slipped 0.1% to $265.48 in pre-market trading. Morgan Stanley boosted... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021
Upgrades B of A Securities upgraded the previous rating for Cimarex Energy Co (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers MediciNova (NASDAQ:MNOV) shares moved upwards by 50.79% to $5.67 during Monday's pre-market session. The market value of their outstanding shares is at $276.5... 
Via Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kindred Biosciences (NASDAQ:KIN) shares moved upwards by 45.26% to $9.21 during Wednesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
RAPT Therapeutics Raises $125M Via Equity At 6% Discount
RAPT Therapeutics Inc (NASDAQ: RAPT) has priced its previously announced underwritten public offering of 3.8 million shares at $33/share. The price represents a 6... 
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs. Significant Points: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers RAPT Therapeutics (NASDAQ:RAPT) s... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles 250 Points; Enochian Biosciences Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.74% to 34,225.89 while the NASDAQ rose 0.45% to 14,132.55. The S&P also fell, dropping 0.27% to 4,236.03. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 111.41% to $39.26 during Monday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as... 
Via Benzinga
Why RAPT Therapeutics Stock Is Crushing It Today
The company reported great results from an early-stage study of its experimental atopic dermatitis drug. 
Via The Motley Fool
RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketing 100%+
RAPT Therapeutics (RAPT) stock is rocketing higher on Monday thanks to positive results from a recent clinical trial of RPT193. 
Via InvestorPlace
Mid-Day Market Update: Nasdaq Rises Over 50 Points; Washington Prime Group Shares Plunge
Midway through trading Monday, the Dow traded down 0.65% to 34,255.66 while the NASDAQ rose 0.41% to 14,126.79. The S&P also fell, dropping 0.23% to 4,237.53. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
40 Stocks Moving In Monday's Mid-Day Session
Gainers Enochian Biosciences, Inc. (NASDAQ: ENOB) shares jumped 127.2% to $10.02. The FDA has accepted Enochian BioSciences Inc's pre-IND (Investigational New Drug) request... 
Via Benzinga
Exposures Product Safety
Mid-Morning Market Update: Markets Mostly Lower; Accenture To Acquire German Engineering Company
Following the market opening Monday, the Dow traded down 0.43% to 34,332.41 while the NASDAQ rose 0.24% to 14,102.61. The S&P also fell, dropping 0.20% to 4,238.80. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study
RAPT Therapeutics Inc (NASDAQ: RAPT) has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback